Thursday, October 21, 2021 11:50:59 AM
The underwriter’s clients will make an offer for the units at a price depending on the total O/S at the time. They’ll expect a significant portion of the total equity in the company, so there’ll be a healthy RS. Those clients will make profit by selling the shares and the free trading warrants, so the PPS will immediately tank down to and below the offering price. The offering price will also be at a discount to the RS PPS, and probably a comparatively large discount, considering the recent exit from bankruptcy, the lack of real progress since that exit, and the price action on the stock. They’ll sell the share of stock for X$, the 2 warrants for Y$, and the sum will be their profit.
Holding through this process was a losing proposition for the 3 others I watched. If there is legitimate interest in the company (as opposed to a flip), there’ll be better buying opportunities later. Read the additional offering materials carefully to be sure they’re going to have the capital for the trials after Auctus gets their slice of the pie. A 4 month holding period is nothing if the flood gates are going to open up afterwards. Just remember what this has been and who really made out in the bankruptcy.
I swear I’ll never use the phrase “you can’t make this stuff up” ever again after being on the OTC. Apparently you can.
Recent BRTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:33:16 PM
- BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs • GlobeNewswire Inc. • 09/19/2024 10:55:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:11:03 PM
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2024 08:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:47:26 PM
- BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine • GlobeNewswire Inc. • 07/23/2024 11:10:00 AM
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM